Researchers at NOVOS Labs describe how a clinically tested blend of 12 ingredients—including glycine, AKG, fisetin, NMN, and magnesium—synergistically reduces oxidative stress, clears senescent cells, and boosts mitochondrial function to support men’s health span and strength.
Key points
Formulation combines 12 clinically studied compounds including glycine, AKG, fisetin, NMN, and magnesium to target multiple aging pathways.
Daily sachet delivery ensures consistent dosing to enhance mitochondrial function, glutathione synthesis, and senescent cell clearance.
Evidence-based blend supports muscle health, inflammation reduction, and cellular repair in men, addressing sarcopenia and metabolic decline.
Why it matters:
This guide presents a multi-modal, evidence-based supplement strategy that targets core cellular aging pathways more comprehensively than single-mechanism products.
Q&A
What are senescent cells?
How does NMN boost cellular health?
Why combine antioxidants and senolytics?
What is sarcopenia and how can supplements help?
Read full article
Academy
Senescent Cells and Senolytics
Senescent cells are cells that have stopped dividing but remain metabolically active. They accumulate in tissues as people age and can contribute to chronic inflammation and tissue dysfunction. While senescence is an important mechanism to prevent the proliferation of damaged cells, the buildup of senescent cells is associated with age-related diseases such as osteoarthritis, atherosclerosis, and neurodegeneration. These cells secrete a range of pro-inflammatory cytokines, growth factors, and proteases—collectively called the senescence-associated secretory phenotype (SASP).
Key features of senescent cells:
- Irreversible growth arrest but metabolic activity
- Resistance to apoptosis
- Senescence-associated beta-galactosidase (SA-β-gal) expression
- Secretion of inflammatory and matrix-remodeling factors (SASP)
The accumulation of senescent cells impairs tissue regeneration and promotes a pro-inflammatory environment. Clearing these cells can rejuvenate tissues, restore function, and improve health span. This is the basis for senolytic therapies, which selectively induce apoptosis in senescent cells without harming healthy cells.
Senolytic agents target pathways that allow senescent cells to resist apoptosis:
- Fisetin: A naturally occurring flavonoid found in strawberries and apples, fisetin has shown senolytic activity by downregulating BCL-2 family proteins, which helps induce apoptosis in senescent cells.
- Dasatinib + Quercetin: This combined treatment blocks pro-survival tyrosine kinase pathways and BCL-2 proteins, effectively clearing senescent adipocyte and endothelial cells in preclinical models.
- Navitoclax (ABT-263): Originally developed as an anti-cancer drug, navitoclax inhibits BCL-2, BCL-XL, and BCL-W, demonstrating senolytic effects in mouse models of aging.
- Other experimental compounds: Researchers are exploring new molecules such as FOXO4-DRI peptides and HSP90 inhibitors that disrupt survival signals specific to senescent cells.
Mechanism of SASP suppression: Senolytic therapy not only clears harmful cells but also reduces the inflammatory factors they release. This can lead to improved tissue function, reduced fibrosis, and mitigation of age-related disabilities.
Role in age-related diseases: The presence of senescent cells in joint cartilage is linked to osteoarthritis, leading to pain and reduced mobility. In vascular tissues, senescence contributes to plaque formation and arterial stiffness, increasing cardiovascular risk. Accumulation in the brain may amplify neuroinflammation and cognitive decline, making senescent cell clearance a target for dementia prevention.
Clinical studies and safety: Early-phase human trials have tested fisetin and dasatinib+quercetin combinations with promising results in reducing markers of senescence and improving physical function. However, dosing and long-term safety need careful evaluation, as some senolytics can affect healthy cell populations at high concentrations.
Assessment methods: Researchers measure senescent cells using biomarkers such as p16INK4a expression, SA-β-gal activity, and SASP factors in blood samples. Advanced imaging techniques and single-cell RNA sequencing are also being developed to quantify senescence in specific tissues non-invasively.
Practical considerations for users: When choosing a supplement regimen targeting senescence, consumers should look for ingredients with demonstrated senolytic or senostatic effects at clinically relevant doses. It is essential to consider product purity, third-party testing, and transparent formulation details to ensure safety and efficacy.
Regulatory landscape: Currently, senolytic compounds are not approved as drugs for aging, although some (e.g., dasatinib) have regulatory approval for other indications. Supplements containing natural senolytics like fisetin are available, but quality and dosage vary. Regulatory agencies are evaluating how to classify these agents, balancing innovation with consumer protection.
Understanding the interplay between senescence and other aging hallmarks—such as telomere attrition, epigenetic alterations, and proteostasis—underscores the need for multi-targeted interventions. Combining senolytics with agents that support mitochondrial function, DNA repair, and antioxidant capacity can create synergistic effects, potentially leading to more robust and lasting improvements in health span.
By understanding the biology of cellular senescence and leveraging senolytic compounds in combination with mitochondrial support and antioxidant ingredients, longevity science offers a comprehensive strategy for promoting healthy aging and delaying the onset of age-related diseases.
